Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Aileron Therapeutics (ALRN) shares
Learn how to easily invest in Aileron Therapeutics shares.
Aileron Therapeutics is a biotechnology business based in the US. Aileron Therapeutics stocks (ALRN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.11 – an increase of 13.4% over the previous week. Aileron Therapeutics employs 9 staff and has a market cap (total outstanding stock value) of $39.9 million.
How to buy stocks in Aileron Therapeutics
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ALRN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Aileron Therapeutics?
- Has coronavirus impacted Aileron Therapeutics shares?
- Aileron Therapeutics shares summary
- Compare share dealing platforms
- Is Aileron Therapeutics stock a buy or sell?
- Aileron Therapeutics performance over time
- Aileron Therapeutics's financials
- How volatile are Aileron Therapeutics shares?
- Does Aileron Therapeutics pay a dividend?
- Other common questions
Aileron Therapeutics stock price (NASDAQ:ALRN)Use our graph to track the performance of ALRN stocks over time.
Aileron Therapeutics shares at a glance
|Latest market close||$0.44|
|52-week range||$0.32 - $1.40|
|50-day moving average||$0.49|
|200-day moving average||$0.70|
|Wall St. target price||$3.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.31|
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Aileron Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Aileron Therapeutics price performance over time
|1 week (2022-05-11)||N/A|
|1 month (2022-04-21)||-18.00%|
|3 months (2022-02-18)||N/A|
|6 months (2021-11-22)||-37.58%|
|1 year (2021-05-21)||-63.93%|
|2 years (2020-05-21)||-41.34%|
|3 years (2019-05-21)||1.15|
|5 years (2017-05-18)||N/A|
Aileron Therapeutics financials
|Gross profit TTM||$-17,008,000|
|Return on assets TTM||-33.4%|
|Return on equity TTM||-56.62%|
|Market capitalisation||$39.9 million|
TTM: trailing 12 months
Aileron Therapeutics share dividends
We're not expecting Aileron Therapeutics to pay a dividend over the next 12 months.
Aileron Therapeutics share price volatility
Over the last 12 months, Aileron Therapeutics's shares have ranged in value from as little as $0.32 up to $1.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aileron Therapeutics's is 2.5716. This would suggest that Aileron Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aileron Therapeutics overview
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics in the news
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
3 Oversold Biotech Stocks to Buy Now
Aileron announces first patients treated in Phase 1b trial of ALRN-6924
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.Read more…
More guides on Finder
Apps like Wealthsimple
Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
How to buy Entain stock in Canada
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
How to buy Kambi Group stock in Canada
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Best brokerage signup bonuses in 2022
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
How to buy Rush Street Interactive stock in Canada
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
How to buy PointsBet stock in Canada
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
How to buy Hanover Bancorp, Inc. (HNVR) stock in Canada when it goes public
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
How to buy PrimeBlock stock in Canada when it goes public
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
How to buy Actelis Networks (ASNS) stock in Canada when it goes public
Everything we know about the Actelis Networks IPO, plus information on how to buy in.